A novel mechanism of action of atorvastatin against cardiovascular risk: A commentary on "Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins"

Free Radical Biology and Medicine

Volumn 43, Issue 9, 2007, Pages 1231-1232

  Emanuele, Enzo ^a   Geroldi, Diego ^a  

^a UNIVERSITY OF PAVIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ADVANCED GLYCATION END PRODUCT; ADVANCED GLYCATION END PRODUCT RECEPTOR; ATORVASTATIN; CHOLESTEROL; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PRAVASTATIN;

ARTICLE; CARDIOVASCULAR RISK; DRUG MECHANISM; GENETIC ENGINEERING; HUMAN; HYPERCHOLESTEROLEMIA; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN GLYCOSYLATION;

EID: 34548800274     PISSN: 08915849     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.freeradbiomed.2007.07.008     Document Type: Note

References (14)

1. Falcone C., Emanuele E., D'Angelo A., Buzzi M.P., Belvito C., Cuccia M., and Geroldi D. Plasma levels of soluble receptor for advanced glycation end products and coronary artery disease in nondiabetic men. Arterioscler. Thromb. Vasc. Biol. 25 (2005) 1032-1037
2. Geroldi D., Falcone C., Emanuele E., D'Angelo A., Calcagnino M., Buzzi M.P., Scioli G.A., and Fogari R. Decreased plasma levels of soluble receptor for advanced glycation end-products in patients with essential hypertension. J. Hypertens. 23 (2005) 1725-1729
3. Basta G., Sironi A.M., Lazzerini G., Del Turco S., Buzzigoli E., Casolaro A., Natali A., Ferrannini E., and Gastaldelli A. Circulating soluble receptor for advanced glycation end products is inversely associated with glycemic control and S100A12 protein. J. Clin. Endocrinol. Metab. 91 (2006) 4628-4634
4. Emanuele E., D'Angelo A., Tomaino C., Binetti G., Guidoni R., Politi P., Bernardi L., Maletta R., Bruni A.C., and Geroldi D. Circulating levels of soluble receptor for advanced glycation end products in Alzheimer disease and vascular dementia. Arch. Neurol. 62 (2005) 1734-1736
5. Pullerits R., Bokarewa M., Dahlberg L., and Tarkowski A. Decreased levels of soluble receptor for advanced glycation end products in patients with rheumatoid arthritis indicating deficient inflammatory control. Arthritis Res. Ther. 7 (2005) R817-R824
6. Yonekura H., Yamamoto Y., Sakurai S., Petrova R.G., Abedin M.J., Li H., Yasui K., Takeuchi M., Makita Z., Takasawa S., Okamoto H., Watanabe T., and Yamamoto H. Novel splice variants of the receptor for advanced glycation end-products expressed in human vascular endothelial cells and pericytes, and their putative roles in diabetes-induced vascular injury. Biochem. J. 370 (2003) 1097-1099
7. Geroldi D., Falcone C., and Emanuele E. Soluble receptor for advanced glycation end products: from disease marker to potential therapeutic target. Curr. Med. Chem. 13 (2006) 1078-1971
8. Naka Y., Bucciarelli L.G., Wendt T., Lee L.K., Rong L.L., Ramasamy R., Yan S.F., and Schmidt A.M. RAGE axis: animal models and novel insights into the vascular complications of diabetes. Arterioscler. Thromb. Vasc. Biol. 24 (2004) 1342-1349
9. Forbes J.M., Thorpe S.R., Thallas-Bonke V., Pete J., Thomas M.C., Deemer E.R., Bassal S., El-Osta A., Long D.M., Panagiotopoulos S., Jerums G., Osicka T.M., and Cooper M.E. Modulation of soluble receptor for advanced glycation end products by angiotensin-converting enzyme-1 inhibition in diabetic nephropathy. J. Am. Soc. Nephrol. 16 (2005) 2363-2372
10. Santilli F., Bucciarelli L., Noto D., Cefalù A.B., Davì V., Ferrante E., Pettinella C., Averna A., Ciabattoni G., and Davì G. Decreased plasma soluble RAGE in patients with hypercholesterolemia: effects of statins. Free Radic. Biol. Med. 43 (2007) 1255-1262
11. Balk E.M., Lau J., Goudas L.C., Jordan H.S., Kupelnick B., Kim L.U., and Karas R.H. Effects of statins on nonlipid serum markers associated with cardiovascular disease: a systematic review. Ann. Intern. Med. 139 (2003) 670-682
12. Okamoto T., Yamagishi S., Inagaki Y., Amano S., Koga K., Abe R., Takeuchi M., Ohno S., Yoshimura A., and Makita Z. Angiogenesis induced by advanced glycation end products and its prevention by cerivastatin. FASEB J. 16 (2002) 1928-1930
13. Cuccurullo C., Iezzi A., Fazia M.L., De Cesare D., Di Francesco A., Muraro R., Bei R., Ucchino S., Spigonardo F., Chiarelli F., Schmidt A.M., Cuccurullo F., Mezzetti A., and Cipollone F. Suppression of RAGE as a basis of simvastatin-dependent plaque stabilization in type 2 diabetes. Arterioscler. Thromb. Vasc. Biol. 26 (2006) 2716-2723
14. Yamagishi S., Nakamura K., Matsui T., and Inoue H. A novel pleiotropic effect of atorvastatin on advanced glycation end product (AGE)-related disorders. Med. Hypotheses 69 (2007) 338-340